Tevogen Inc. (Nasdaq: TVGN) announced on September 30, 2026, that it has successfully regained compliance with Nasdaq’s continued listing requirements. The notification was received on September 29, 2026, from The Nasdaq Stock Market LLC.
The company confirmed that it has satisfied the $50 million minimum market value of the listed securities requirement under Nasdaq Listing Rule 5450(b)(2)(A). This requirement applies to continued listing on The Nasdaq Global Market.
Tevogen noted that this matter is now closed. The company stated that it had previously received written notice on September 9, 2026, confirming compliance with the minimum market value of publicly held shares requirement under Nasdaq Listing Rules 5450(B)(2)(C) and 5450(B)(3)(C). With both compliance matters satisfied, the related issues are resolved.
The company’s press release, dated September 30, 2026, furnishes additional details regarding the notification. Tevogen is described as an integrated healthcare enterprise that combines biotechnology, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines.
